Postdoc researcher for the European Fair Pricing Network

Postdoc researcher for the European Fair Pricing Network

Published Deadline Location
6 Feb 1 Mar Amsterdam

Job description

The Netherlands Cancer Institute (NKI) is an independent research institute located in Amsterdam. The Institute covers all major areas of molecular and cellular cancer biology, with special emphasis on immunology, cancer cell biology and translational research; increasingly health technology assessment (HTA) and health economic studies are performed in early stages of research that can lead to clinical innovations. The Netherlands Cancer Institute and the Antoni van Leeuwenhoek Hospital form an comprehensive cancer center, combining a research laboratory and a hospital under one roof in a single, independent organization This research is focused on improving cancer treatment through imaging and molecular diagnostics, new medicine, immunotherapy, improved operating techniques, more effective radiotherapy, and combinations of these, HTA, epidemiology and psychosocial research.

About the research
The EFPN research unit will focus on monitoring and providing information on specified themes and questions related to medicines access and equity. The research agenda shall be demand-driven and take the research need of founding partners into account, while focusing on an collaborative European approach. There will be close cooperation with the OECI working group on health economics.

The EFPN research unit will monitor and provide information with a focus on three research questions in the first two years:

  1. Access: Which highly valuable medicines are available for specific populations/population subgroups?
  2. Transparency: At which (actual) price are the above medicines available?
  3. Accountability: How high is the current amount of public investment in pharmaceutical R&D?

About the position
We are looking for a Postdoc to start our research team by early 2020 and welcome reactions from interested candidates from now on.

The Postdoc shall be responsible for overseeing the research according to the EFPN proposal, amongst others:
I. Build a scientific network corresponding with the research agenda
II. Ensuring the quality of the data and research
III. Supervise work of PhD
IV. Ensure alignment with advocacy unit

The PostDoc position is 0.2 FTE dedicated to the EFPN project. Depending on the exact background and profile of the candidate and if appreciated, we will try to extend the appointment up to 0.8 FTE, regarding e.g. new/related projects on early Health Technology Assessment in oncology.

Specifications

The Netherlands Cancer Institute

Requirements

You are expected to have a master degree in economics, health economics, health services research or international public health, or another relevant master degree, with a PhD that was based on work in the field of Health Technology Assessment or Health Economics. Moreover, you must have excellent English communication and writing skills.

In the final round of selection the remaining candidates will be provided with the full EFPN proposal (although still to be finalized by those to be employed) in order to reflect in detail on the initiative. Although the EFPN unit is located in Amsterdam, we especially invite candidates from other EU countries than the Netherlands to react.

Conditions of employment

Fixed-term contract: 4 years.

The temporary employment will be for a period of 4 years. The gross salary per month will be from €3.664,- to € 4.111,- according to the standard (100%) Postdoc scales and depends on previous experience. The terms of employment will be in accordance with the CAO Ziekenhuizen (Collective Labour Agreement for Hospitals).

Amsterdam is a very lively city with many cultural amenities. The institute is located within a 20 minute tram or bicycle ride from the city center and within 20 minutes from Schiphol airport by car, bus or bicycle.

Employer

The Antoni van Leeuwenhoek - Netherlands Cancer Institute (ALV-NKI)

The Antoni van Leeuwenhoek - Netherlands Cancer Institute (ALV-NKI) is an independent research institute located in Amsterdam. The Institute covers all major areas of molecular and cellular cancer biology, with special emphasis on immunology, cancer cell biology and translational research; increasingly health technology assessment (HTA) and health economic studies are performed in early stages of research that can lead to clinical innovations. The Netherlands Cancer Institute and the Antoni van Leeuwenhoek Hospital form an comprehensive cancer center, combining a research laboratory and a hospital under one roof in a single, independent organization This research is focused on improving cancer treatment through imaging and molecular diagnostics, new medicine, immunotherapy, improved operating techniques, more effective radiotherapy, and combinations of these, HTA, epidemiology and psychosocial research.

Additional information

For further information and addresses visit our home page (www.nki.nl) or contact Prof. Wim H. van Harten (w.v.harten@nki.nl) or dr. Valesca.P. Retèl (v.retel@nki.nl).

Interested in applying? Please click the 'apply now' button which will offer a link at the bottom of this webpage. This will refer you to an application form of ALV-NKI. Please submit an electronic copy of your CV, preferably with names and contact information of referents, and a cover letter describing education, research experience and research interests.
 

Specifications

  • Postdoc
  • Natural sciences; Health; Economics
  • 8—36 hours per week
  • €3664—€4111 per month
  • Doctorate
  • AT Postdoc Fair pricing

Employer

The Netherlands Cancer Institute

Learn more about this employer

Location

Plesmanlaan 121, 1066 CX, Amsterdam

View on Google Maps

X

Apply for this job

Apply for this job

This application process is managed by the employer (The Netherlands Cancer Institute). Please contact the employer for questions regarding your application.

Apply for this job via the employer's website

Application procedure

Application procedure

Make sure to apply no later than 1 Mar 2020 23:59 (Europe/Amsterdam).